| Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers JJ Carlson, SD Sullivan, LP Garrison, PJ Neumann, DL Veenstra Health policy 96 (3), 179-190, 2010 | 277 | 2010 |
| Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial J Cassidy, JY Douillard, C Twelves, JJ McKendrick, W Scheithauer, ... British journal of cancer 94 (8), 1122-1129, 2006 | 137 | 2006 |
| Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial J Cassidy, JY Douillard, C Twelves, JJ McKendrick, W Scheithauer, ... British journal of cancer 94 (8), 1122-1129, 2006 | 137 | 2006 |
| Can’t get no satisfaction? Will pay for performance help? A Towse, LP Garrison Pharmacoeconomics 28 (2), 93-102, 2010 | 120 | 2010 |
| Challenges in the development and reimbursement of personalized medicine—payer and manufacturer perspectives and implications for health economics and outcomes research: a … E Faulkner, L Annemans, L Garrison, M Helfand, AP Holtorf, J Hornberger, ... Value in Health 15 (8), 1162-1171, 2012 | 117 | 2012 |
| Global eradication of measles: an epidemiologic and economic evaluation A Levin, C Burgess, LP Garrison, C Bauch, J Babigumira, E Simons, ... The Journal of infectious diseases 204 (suppl_1), S98-S106, 2011 | 83 | 2011 |
| Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force Report—Part I JW Hay, J Smeeding, NV Carroll, M Drummond, LP Garrison, EC Mansley, ... Value in Health 13 (1), 3-7, 2010 | 82 | 2010 |
| The Potential Clinical and Economic Outcomes of Pharmacogenomic Approaches to EGFR‐Tyrosine Kinase Inhibitor Therapy in Non–Small‐Cell Lung Cancer JJ Carlson, LP Garrison, SD Ramsey, DL Veenstra Value in Health 12 (1), 20-27, 2009 | 82 | 2009 |
| Estimating the effect of changes in body mass index on health state preferences Z Hakim, A Wolf, LP Garrison Pharmacoeconomics 20 (6), 393-404, 2002 | 81 | 2002 |
| A formal risk-benefit framework for genomic tests: facilitating the appropriate translation of genomics into clinical practice DL Veenstra, JA Roth, LP Garrison, SD Ramsey, W Burke Genetics in Medicine 12 (11), 686-693, 2010 | 78 | 2010 |
| The use, safety and cost of bariatric surgery before and after Medicare’s national coverage decision DR Flum, S Kwon, K MacLeod, B Wang, R Alfonso-Cristancho, ... Annals of surgery 254 (6), 860, 2011 | 74 | 2011 |
| Cost-effectiveness of bariatric surgical procedures for the treatment of severe obesity BCM Wang, ES Wong, R Alfonso-Cristancho, H He, DR Flum, ... The European Journal of Health Economics 15 (3), 253-263, 2014 | 69 | 2014 |
| Weight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone after 26 weeks … JH Best, RR Rubin, M Peyrot, Y Li, P Yan, J Malloy, LP Garrison Diabetes Care 34 (2), 314-319, 2011 | 58 | 2011 |
| The drug budget silo mentality in Europe: an overview L Garrison, A Towse Value in Health 6, S1-S9, 2003 | 54 | 2003 |
| Cost effectiveness of a pharmacy-only refill program in a large urban HIV/AIDS clinic in Uganda JB Babigumira, B Castelnuovo, A Stergachis, A Kiragga, P Shaefer, ... PLoS One 6 (3), e18193, 2011 | 52 | 2011 |
| Current status and trends in performance-based risk-sharing arrangements between healthcare payers and medical product manufacturers JJ Carlson, KS Gries, K Yeung, SD Sullivan, LP Garrison Applied health economics and health policy 12 (3), 231-238, 2014 | 51 | 2014 |
| Potential impact of task-shifting on costs of antiretroviral therapy and physician supply in Uganda JB Babigumira, B Castelnuovo, M Lamorde, A Kambugu, A Stergachis, ... BMC Health Services Research 9 (1), 1-6, 2009 | 51 | 2009 |
| The cost effectiveness of mycophenolate mofetil in the first year after primary cadaveric transplant. US Renal Transplant Mycophenolate Mofetil Study Group. SD Sullivan, LP Garrison, JH Best Journal of the American Society of Nephrology 8 (10), 1592-1598, 1997 | 51 | 1997 |
| Performance-based risk-sharing arrangements: an updated international review JJ Carlson, S Chen, LP Garrison Pharmacoeconomics 35 (10), 1063-1072, 2017 | 48 | 2017 |
| Strategic use of pharmacoeconomic research in early drug development and global pricing K Clemens, LP Garrison, A Jones, F Macdonald Pharmacoeconomics 4 (5), 315-322, 1993 | 48 | 1993 |
